Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 5

MACE in the overall population by number of CV risk factors present. n is the number of patients with an event; N is the number of patients in treatment group. CI confidence interval, CTRL control, DAPA dapagliflozin, HR hazard ratio, MACE major adverse cardiovascular events (CV death, myocardial infarction and stroke), p–y = patient–years

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840